Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Novo Nordisk A/S Over Securities Laws Violations

Strategic Insights

— 1 min read

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, has notified investors of a class action lawsuit filed against Novo Nordisk A/S ("Novo Nordisk") and certain of its officers. The lawsuit seeks to recover damages for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or acquired Novo Nordisk securities between May 7, 2025, and July 28, 2025. Investors are encouraged to join the case by visiting the firm's website.

Key Takeaways:

  • The lawsuit alleges that Novo Nordisk made materially false and misleading statements regarding its growth potential and misrepresented the likelihood of patients transitioning to Novo Nordisk's branded alternatives.
  • The class period spans from May 7, 2025, to July 28, 2025, inclusive, during which the company allegedly overstated the size of the GLP-1 market and its ability to penetrate it.
  • The lawsuit accuses Novo Nordisk of failing to disclose the impact of the personalization exception to the compounded GLP-1 exclusion on its growth prospects.
  • The firm, Bronstein, Gewirtz & Grossman, LLC, has recovered hundreds of millions of dollars for investors nationwide in securities fraud class actions and shareholder derivative suits.
  • Investors who suffered a loss in Novo Nordisk have until September 30, 2025, to request that the Court appoint them as lead plaintiff.
  • The firm represents investors in class actions on a contingency fee basis, with no cost to the investors if the firm is unsuccessful.

Statistics:

  • The class period spans from May 7, 2025, to July 28, 2025.
  • The lawsuit was filed against Novo Nordisk A/S and certain of its officers.
  • Investors have up to September 30, 2025, to request lead plaintiff designation.
  • The firm has recovered hundreds of millions of dollars for investors nationwide in securities fraud class actions.

Sources:

  • Bronstein, Gewirtz & Grossman, LLC website
  • NYSE: NVO - Novo Nordisk A/S
  • COMTEX_468304326/2010/2025-08-25T15:59:47

Read more